科研之友
微信
新浪微博
Facebook
分享链接
摘要
Lung cancer is the most common malignant tumor. As the first - generation oral small - molecule tyrosine kinase inhibitor independently developed in China, apatinib can block many kinds of signaling pathways with high selectivity, and play an anti-tumor effect by inhibiting tumor angiogenesis, and the adverse reactions are controllable. More and more studies have shown that apatinib can be used for the second- line and beyond treatment of patients with advanced non - small cell lung cancer. This article reviews the mechanisms and clinical studies of apatinib in treatment of lung cancer.
- 单位
